Clinical Trials Logo

Clinical Trial Summary

With the advent of measures to try to decrease the incidence of transfusion-related acute lung injury (TRALI), the Blood Bank industry is attempting to avoid collection of plasma from female donors who have been pregnant in order to reduce the transfusion of plasma that may contain HLA antibodies. This has led to a decrease in the number of donors available for the production of fresh frozen plasma (FFP). Per Blood Bank regulatory standards in the United States, FFP must be frozen within 8 hours of collection. Plasma that is frozen within 24 hours of collection is called FP24, and it is produced when whole blood cannot be processed within the 8-hour time period for the generation of FFP. Studies of coagulation factors in FFP and FP24 have shown that coagulation factor activities are adequate to maintain hemostasis in both products. Many hospitals are using FFP and FP24 interchangeably in adults, and occasional hospitals are using these products interchangeably in neonates. However, studies concerning the use of FP24 in neonates have not been performed.

The investigators propose a single center prospective pilot study comparing the clinical efficacy of FFP vs. FP24 in 50 nonsurgical neonates and babies up to age 6 months requiring plasma for an International Normalization Ratio (INR) of 1.5 or more.

This protocol describes a pilot study to compare the use of FFP with FP24 in nonsurgical neonates. Use of plasma in these cases is mostly for patients with perinatal hypoxia or necrotizing enterocolitis and an INR of 1.5 or more. Transfusion of plasma (10 to 15 ml/kg) is performed for these patients approximately every 8, 12, or 24 hours, as deemed indicated by the patient's clinicians, and monitored with prothrombin time (PT), partial thromboplastin time (PTT), and INR.


Clinical Trial Description

Half the patients will be randomized by the Blood Bank to receive FFP, the other half FP24. All patients will be monitored in the usual way, with careful clinical observation and with PT/PTT/INR, to be drawn once in 12 or 24 hours based on clinical necessity. If a patient needs additional transfusions, the same type of product will be administered for each episode. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02774317
Study type Interventional
Source University of Chicago
Contact
Status Withdrawn
Phase Phase 4
Start date October 2017
Completion date December 2020

See also
  Status Clinical Trial Phase
Recruiting NCT02239991 - Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant N/A
Completed NCT01435304 - The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00091494 - Socioeconomic Patterning of Inflammation and Hemostasis - Ancillary to MESA N/A
Completed NCT00005481 - Epidemiology of Impaired Coagulant Balance in Diabetes N/A
Recruiting NCT02379104 - ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals N/A
Recruiting NCT01930916 - Accuracy of a Portable International Normalized Ratio Monitor in Elderly Patients N/A
Completed NCT00168090 - Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Phase 4
Completed NCT01787552 - A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF Phase 1/Phase 2
Not yet recruiting NCT02782338 - The Effect of Voltaren-ophtha 0.1% Eye Drops on INR Levels (International Normalized Ratio) in Patients Taking Warfarin N/A
Unknown status NCT01349712 - Study to Test the Accuracy of a Prototype Handheld PT/INR Device N/A
Completed NCT01143909 - Transfusion of Fresh Frozen Plasma in Non-bleeding Intensive Care Unit (ICU) Patients N/A
Recruiting NCT04762550 - Thrombin Generation in Liver Transplant Surgery
Withdrawn NCT01221389 - Study Using Plasma for Patients Requiring Emergency Surgery Phase 4
Withdrawn NCT00233246 - Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures Phase 3
Recruiting NCT03884725 - Fibrinogen Concentrate In Children Cardiac Surgery 2 Phase 4
Completed NCT00086476 - Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles N/A
Completed NCT00516126 - Goal-orientated Therapy of Perioperative Disturbance in Hemostasis in Cardiac Surgery Phase 4
Completed NCT00708435 - Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy Phase 3
Recruiting NCT00214656 - "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery Phase 3